Search

Learn how Kéara was able to maintain her quality of life after treatment for triple negative breast cancer.

… Monday, April 4, 2022 When Kéara Richardson was diagnosed with triple-negative breast cancer at just 37, she feared her life would never be the same again. But Memorial Sloan Kettering Cancer Center (MSK) offered her an innovative treatment that puts chemotherapy before breast cancer surgery . This approach

Scientists are learning how tumors develop resistance to drugs — and what can be done about it.

… Thursday, July 27, 2017 Summary Drugs targeting a particular mutation in cancer cells can be an effective form of therapy. But the beneficial effects are often short-lived as tumors quickly develop resistance. New research is casting light on how this resistance evolves and what treatment approaches

Meet Victoria “Vikki” Mills, Associate Director of Research Administration Operations at Memorial Sloan Kettering, who is deeply satisfied with her work and delighted with her family, which will soon expand — Vikki is expecting her second child in August with her fiancée, Shauna.

… Monday, June 28, 2021 Within two minutes of meeting Victoria “Vikki” Mills, Associate Director of Research Administration Operations at Memorial Sloan Kettering, you recognize that you are in the presence of a powerful, positive force to be reckoned with, someone who is happily and energetically creating

Scientists at Sloan Kettering Institute have discovered that the α6ß4 integrin, one of several receptor proteins, plays a key role in signaling for the formation of new blood vessels for a tumor, a process called tumor angiogenesis. By blocking the signaling activity of the α6ß4 subunit of this integrin on vascular cells, researchers found they could slow the growth of tumors.

… Tuesday, February 8, 2005 Summary Scientists at Sloan Kettering Institute have discovered that the α6ß4 integrin, one of several receptor proteins, plays a key role in signaling for the formation of new blood vessels for a tumor, a process called tumor angiogenesis. By blocking the signaling activity

MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.

… Tuesday, April 11, 2017 Summary An MSK expert comments on a new US Preventive Services Task Force (USPSTF) guideline regarding a type of prostate cancer screening. The USPSTF has issued an updated guideline for prostate-specific-antigen-based screening for prostate cancer. The new guideline states that

Researchers have gained new understanding of how tumors metastasize by studying the behavior of exceptional breast and lung cancer cells that are capable of entering the brain and surviving there.

… Thursday, February 27, 2014 Summary Researchers have gained new understanding of how tumors metastasize by studying the behavior of exceptional breast and lung cancer cells that are capable of entering the brain and surviving there. Metastasis , the process that allows some cancer cells to break off

Combining checkpoint blockade with engineered T cells may lead to longer-lasting results in patients with breast cancer, lung cancer, and other solid tumors.

… Thursday, July 28, 2016 Summary Memorial Sloan Kettering is a leader in developing immunotherapies to treat cancer. Now researchers say combining two different immune approaches may better treat solid tumors. The immunotherapy treatment known as CAR T cell therapy , while still experimental, is showing

Cancers linked to HPV are on the rise. But only a little over half of all adolescents in the U.S. got the full series of vaccinations. In this Q&A, Chrisann Kyi talks about why it's so important for young people to get vaccinated.

… Thursday, September 27, 2018 Summary HPV-associated cancers are on the rise, but only about half of all adolescents in the United States have received the full series of shots. In this Q & A, Chrisann Kyi talks about why it’s so important for young people to get vaccinated. Update: On October 5, 2018

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute explores ways to limit heart damage from chemotherapy and radiation; examines genomic differences between primary and metastatic tumors in bladder cancer; aims to understand the safety of check point inhibitor therapy for patients who are obese; and investigates a potential therapeutic approach against acute myeloid leukemia.

… Friday, December 23, 2022 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — explores ways to limit heart damage from chemotherapy and radiation; examines genomic differences between primary and metastatic tumors in bladder

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its fiscal year 2022 financial results today.

… Friday, April 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its fiscal year 2022 financial results today: MSK generated an operating loss of $248.1 million for fiscal year 2022, which was driven in large part by inflationary pressures that contributed